EUVIMEDEUVIMED entdecken
Crossref

Does the Accuracy of Prostate-specific Antigen Density in Identifying Clinically Significant Prostate Cancer Change with Prostate Volume?

Leonardo Quarta, Francesco Pellegrino, Armando Stabile, Pietro Scilipoti, Mattia Longoni, Donato Cannoletta, Paolo Zaurito, Alfonso Santangelo, Alessandro Viti, Andrea Cosenza, Riccardo Leni, Antony Pellegrino und 9 weitere

European Urology Focus · 2026-10 · 12 (5) · 893-899

DOI: 10.1016/j.euf.2025.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Leonardo Quarta und 20 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Ins…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Prostate. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Prostate-specific antigen density (PSAD) can improve the accuracy of the prostate cancer (PCa) diagnostic pathway when combined with multiparametric magnetic resonance imaging (mpMRI). However, it is unknown how the risk of clinically significant PCa (csPCa) at each PSAD value varies according to prostate volume in patients with positive mpMRI findings (Prostate Imaging-Reporting and Data System [PI-RADS] score ≥3). METHODS: The study included 1731 patients with positive mpMRI findings who underwent MRI-targeted biopsy (TBx) plus systematic biopsy (SBx). The predicted risk of csPCa as a function of PSAD was plotted to explore how the appropriate PSAD cutoff varies according to prostate volume. KEY FINDINGS AND LIMITATIONS: Overall, 30%, 48%, and 22% of patients had PI-RADS 3, 4, and 5 lesions, respectively. csPCa was diagnosed in 56% of patients. Overall, the median predicted risk of csPCa corresponding to PSAD of 0.10 ng/ml/ml was 37% for prostate volume 10% irrespective of their PSAD. For prostate volume >40 ml, the PSAD cutoff corresponding to csPCa risk of 10% varied between 0.10 and 0.15 ng/ml/ml. The main limitations of the study include the retrospective design and the tertiary referral center setting. CONCLUSIONS AND CLINICAL IMPLICATIONS: The predictive value of PSAD for csPCa detection varies according to prostate volume. The added value of PSAD in detecting csPCa in men with PI-RADS 3 lesions is greater for those with prostate volume >40 ml.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenProstateHumansMaleMultiparametric Magnetic Resonance ImagingOrgan SizeMiddle AgedAgedRetrospective StudiesPredictive Value of TestsImage-Guided BiopsyClinical Relevance

Stichwörter der Autor:innen

Multiparametric magnetic resonance imagingProstate biopsyProstate cancerProstate volumeProstate-specific antigen density

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: quarta.leonardo@hsr.it.
  • Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
  • Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Ital…

Zitieren

APA

Quarta, L., Pellegrino, F., Stabile, A., Scilipoti, P., Longoni, M., Cannoletta, D., Zaurito, P., Santangelo, A., Viti, A., Cosenza, A., Leni, R., Pellegrino, A., Barletta, F., Scuderi, S., Robesti, D., Mazzone, E., Brembilla, G., Cobelli, F., Montorsi, F., …, & Gandaglia, G. (2026). Does the Accuracy of Prostate-specific Antigen Density in Identifying Clinically Significant Prostate Cancer Change with Prostate Volume?. European Urology Focus, 12(5), 893-899. https://doi.org/10.1016/j.euf.2025.10.005

Vancouver

Quarta L, Pellegrino F, Stabile A, Scilipoti P, Longoni M, Cannoletta D, et al. Does the Accuracy of Prostate-specific Antigen Density in Identifying Clinically Significant Prostate Cancer Change with Prostate Volume?. European Urology Focus. 2026;12(5):893-899. doi:10.1016/j.euf.2025.10.005

BibTeX
@article{Quarta2026,
  author = {Quarta, Leonardo and Pellegrino, Francesco and Stabile, Armando and Scilipoti, Pietro and Longoni, Mattia and Cannoletta, Donato and Zaurito, Paolo and Santangelo, Alfonso and Viti, Alessandro and Cosenza, Andrea and Leni, Riccardo and Pellegrino, Antony and Barletta, Francesco and Scuderi, Simone and Robesti, Daniele and Mazzone, Elio and Brembilla, Giorgio and Cobelli, Francesco De and Montorsi, Francesco and Briganti, Alberto and Gandaglia, Giorgio},
  title = {Does the Accuracy of Prostate-specific Antigen Density in Identifying Clinically Significant Prostate Cancer Change with Prostate Volume?},
  journal = {European Urology Focus},
  year = {2026},
  volume = {12},
  number = {5},
  pages = {893--899},
  doi = {10.1016/j.euf.2025.10.005}
}
Kostenlos starten →